Amicus Therapeutics, Inc.
FOLDDelisted Apr 27, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001178879
Amicus Therapeutics, Inc. was delisted on Apr 27, 2026; its insiders filed their last Form 4 on Apr 27, 2026; 298 institutions reported holding it in 13F filings for Q1 2026, worth $4.81B in total; Soros Fund Management was the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Amicus Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 259 | 1 | 293 | +35 |
| Shares | 315.3M | 24.4M | 310.0M | +19.1M (+6.6%) |
| Value | $3.13B | $241.8M | $3.31B | +$425.5M (+14.7%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (60)
Institutions that held Amicus Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
Sold out (25)
Institutions that held Amicus Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Great Point Partners LLC | 1,495,500 | $14.8M |
| M&G Plc | 748,451 | $7.48M |
| Saturn V Capital Management LLC | 713,536 | $7.08M |
| Ambassador Advisors, LLC | 281,659 | $2.79M |
| Bank of Montreal | 107,369 | $1.10M |
| Eisler Capital (US) LLC | 83,110 | $824.5K |
| EntryPoint Capital, LLC | 40,803 | $404.8K |
| Caption Management, LLC | 21,900 | $217.2K |
| Oxford Asset Management LLP | 19,099 | $189.5K |
| Entropy Technologies, LP | 18,575 | $184.3K |
| Park Avenue Securities LLC | 14,513 | $144.0K |
| Sanctuary Advisors, LLC | 13,445 | $138.2K |
| Mount Yale Investment Advisors, LLC | 11,431 | $113.4K |
| Alpine Global Management, LLC | 11,297 | $112.1K |
| Omers Administration Corp | 10,300 | $102.2K |
| MML Investors Services, LLC | 10,252 | $102.0K |
| Fulton Bank, N.A. | 10,257 | $101.7K |
| Pacer Advisors, Inc. | 2,597 | $25.8K |
| Ashton Thomas Private Wealth, LLC | 1,183 | $11.7K |
| Versant Capital Management, Inc | 593 | $5.88K |
| GWM Advisors LLC | 585 | $5.80K |
| Massmutual Trust Co FSB | 380 | $3.77K |
| Stephens Consulting, LLC | 189 | $1.88K |
| Itau Unibanco Holding S.A. | 177 | $1.76K |
| Innealta Capital, LLC | 47 | $466 |
Not filed for Q3 2024 yet (1)
Institutions that held Amicus Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 24,371,659 | $241.8M |